KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Gains from Sales and Divestitures (2019 - 2025)

BioNTech SE (BNTX) posted Gains from Sales and Divestitures of -$452783.9 for Q2 2025, down 110.23% on a QoQ basis from -$215377.5 in Q2 2024, and down 110.23% year-over-year from $4.4 million in Q2 2024.

BioNTech SE (BNTX) has 6 years of Gains from Sales and Divestitures data on file, last reported at -$452783.9 in Q2 2025.

  • In Q2 2025, Gains from Sales and Divestitures fell 110.23% year-over-year to -$452783.9; the TTM figure through Jun 2025 stood at -$452783.9 (down 110.23% YoY), while the FY2021 annual figure was $5.26, up 635.6% from the prior year.
  • Gains from Sales and Divestitures fell to -$452783.9 in Q2 2025, from -$215377.5 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $481708.6 in Q2 2021 and bottomed at -$452783.9 in Q2 2025.
  • A 4-year average of $4494.0 and a median of $2.75 in 2021 frame the typical range for Gains from Sales and Divestitures.
  • Annual changes were most pronounced in 2021 — Gains from Sales and Divestitures surged 635.6% — and 2025, when it plunged 110.23%.
  • Year by year, Gains from Sales and Divestitures stood at $5.26 in 2021, then surged by 4055402.37% to $213411.3 in 2022, then slumped by 200.92% to -$215377.5 in 2024, then slumped by 110.23% to -$452783.9 in 2025.
  • The last three Gains from Sales and Divestitures figures came in at -$452783.9 (Q2 2025), -$215377.5 (Q2 2024), and $213411.3 (Q2 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 BioNTech SE 27.66 Bn 7.53 Bn 668.28 Mn

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 -452,783.88
Jun 30, 2025 -452,783.88
Jun 30, 2024 -215,377.52
Jun 30, 2024 -215,377.52
Jun 30, 2022 213,411.34
Jun 30, 2022 213,411.34
Dec 31, 2021 5.26
Dec 31, 2021 5.26
Jun 30, 2021 481,708.57
Jun 30, 2021 481,708.57
Mar 31, 2021 0.24
Mar 31, 2021 0.24
Dec 31, 2020 0.72
Dec 31, 2020 0.72
Mar 31, 2020 110,393.90
Mar 31, 2020 110,393.90
Dec 31, 2019 0.55
Dec 31, 2019 0.55